PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩70 per share · Prices as of the 2026-10-02 close
BNC Korea grew 2025 revenue to KRW 95.9 billion, yet operating margin collapsed from 12.0% to 1.7%, and the company posted operating losses in three of the four quarters from Q3 2025, leaving profitability recovery as the key watch item.
2025 consolidated revenue rose 7.5% to KRW 95.9 billion, while operating profit fell 84.8% to KRW 1.63 billion and net profit dropped 78.7% to KRW 2.05 billion.
Across the four most recent quarters (Q3 2025-Q2 2026), operating losses persisted in most periods, though the loss narrowed in Q2 2026.
The aesthetic product segment (62% of 2025 revenue) drove growth, while the surgical/procedural product segment contracted.
Premium cosmetics brand I.ST completed entry into Amazon US and is preparing a New York pop-up store for the second half of 2026.
GLP-1-class biobetter and biosimilar research based on the Sejong GMP facility is underway, but remains an early-stage program requiring further time before commercialization.
BNC Korea was established in 2007 and listed on KOSDAQ in December 2019 as an aesthetic-medical and biotech company. The company processes hyaluronic acid, collagen, and botulinum toxin to develop medical devices, pharmaceuticals, and cosmeceutical products, and also operates a bio-distribution business.
Its flagship products include the HA filler Cuzel, the adhesion barrier Hybery, the collagen wound dressing Gentacue, and the botulinum toxin product Bienox, which received export approval in January 2020.
In the 2025 revenue mix, the aesthetic product segment was largest at KRW 59.1 billion (62% share), followed by the surgical/procedural product segment at KRW 9.1 billion (9%) and the aesthetic device segment at KRW 2.6 billion (3%), while distribution of third-party products including reagents and test equipment contributed KRW 24.6 billion, or 25.7% of total revenue.
The company operates a pharmaceutical GMP manufacturing facility in Sejong that produces solid-dosage finished drugs and botulinum toxin formulations, with plans to expand into biopharmaceutical manufacturing.
More recently, the company has pushed overseas distribution through its premium cosmetics brand I.ST, including entry into Amazon US and participation in European and Middle Eastern beauty trade shows.
In the filler and toxin market, the company competes against a broad field of domestic players including Hugel, Medytox, Daewoong Pharmaceutical, Jetema, Innobio, and Pharma Research Bio across multiple products and regions.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩24.6B | ₩1.6B | 6.5% |
| 2025Q3 | ₩22.3B | -₩1.4B | −6.3% |
| 2025Q4 | ₩23.6B | -₩2.4B | −10.0% |
| 2026Q1 | ₩20.7B | -₩1.5B | −7.1% |
| 2026Q2 | ₩24.6B | -₩400M | −1.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩42.3B | -₩10.1B | -₩44.7B | −23.9% | −24.3% | 22.3% |
| 2023 | ₩81B | ₩6B | ₩25.7B | 7.5% | 12.3% | 10.2% |
| 2024 | ₩89.2B | ₩10.7B | ₩13.3B | 12.0% | 5.8% | 12.9% |
| 2025 | ₩95.9B | ₩1.6B | ₩2B | 1.7% | 0.9% | 16.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
2025 consolidated revenue rose 7.5% year-on-year to KRW 95.9 billion from KRW 89.2 billion, but operating profit plunged 84.8% to KRW 1.63 billion from KRW 10.7 billion, with operating margin falling sharply from 12.0% to 1.7%. Net profit attributable to owners fell 78.7% to KRW 2.05 billion from KRW 13.3 billion.
On a quarterly basis, Q2 2025 was relatively solid with revenue of KRW 24.6 billion and operating profit of KRW 1.6 billion, but Q3 revenue of KRW 22.3 billion came with an operating loss of KRW 1.4 billion, and Q4 revenue of KRW 23.6 billion carried an operating loss of KRW 2.4 billion, extending losses through the second half.
Into 2026, Q1 revenue of KRW 20.7 billion still posted an operating loss of KRW 1.5 billion, while Q2 revenue recovered to KRW 24.6 billion with the operating loss narrowing to KRW 0.37 billion.
Net profit attributable to owners was also negative for four consecutive quarters: Q3 2025 (-KRW 0.17 billion), Q4 2025 (-KRW 3.16 billion), Q1 2026 (-KRW 1.03 billion), and Q2 2026 (-KRW 1.13 billion).
Behind this profit deterioration lie a declining gross margin (from 46.8% to 41.1%) and a sharp increase in R&D spending (from KRW 2.7 billion to KRW 5.1 billion, up 89.8%).
The balance sheet has remained comparatively stable, with a low debt ratio of 16.1% and operating cash flow generating a net inflow of KRW 7.16 billion.
The aesthetic-medical product market is expanding on the back of population aging and rising beauty consciousness, with the segment expected to grow at a compound annual rate of 10.2% from USD 13.2 billion in 2023 to USD 31.3 billion in 2032.
Domestic Korean players are accelerating overseas expansion on the back of the so-called K-Medi wave, and the filler and toxin markets show a fragmented competitive structure with numerous domestic and international players.
In the botulinum toxin segment, competition has intensified as, alongside leading players such as Daewoong Pharmaceutical, Hugel, and Medytox, a number of later entrants including Pharma Research Bio, Innobio, Genetoxin, and Korea BMI have obtained state shipment approvals.
At the same time, the GLP-1-class obesity and diabetes treatment market is a high-growth area drawing in not only global pharmaceutical majors but also multiple domestic firms expanding their pipelines, and BNC Korea is conducting early-stage research targeting this space as well.
In cosmetics, commentary suggests K-beauty is becoming an established pillar of the global lifestyle beauty market beyond a passing trend, supporting continued export expansion opportunities.
BNC Korea is a relatively small-cap player by revenue scale, trailing larger competitors in brand recognition and financial firepower, but is pursuing differentiation through its Sejong GMP infrastructure and multi-product portfolio.
The company has built a presence in Europe and the Middle East through its premium cosmetics brand I.ST and has completed entry into Amazon US, with a New York Manhattan pop-up store planned for the second half of 2026.
Earlier in 2026, the company said it participated in Beauty Istanbul in Turkey in May and Beauty Düsseldorf in Germany in March, drawing interest from overseas buyers centered on its PDRN skincare line.
Domestically, the company is simultaneously expanding pharmacy distribution channels and marketing targeted at foreign tourists.
Over the longer term, the company has pursued development of GLP-1-class biosimilar and biobetter treatments for diabetes and obesity based on its Sejong pharmaceutical GMP facility, reportedly working with ProAptech on cell line development and mass production technology.
However, this pipeline remains at an early research stage, with clinical entry and regulatory approval still ahead before any commercialization, implying a lengthy timeline.
While the aesthetic product segment continues to show revenue recovery, the decline in the surgical/procedural segment and the growing weight of the distribution business remain variables that could continue to affect the overall profit structure.
Future results are likely to hinge on the pace of recovery in aesthetic product sales, management of R&D spending, and whether the overseas cosmetics business can turn profitable.
The company's earnings trajectory has swung from a large net loss in 2022 to profitability in 2023-2024, and then back to a sharp profit decline in 2025.
Over the most recent four quarters combined, the company has been in a net loss position, making conventional price-to-earnings comparisons difficult, which tends to shift market attention toward the future earnings recovery path rather than trailing results.
The share price trades below book value per share, placing it in a discount range relative to net assets. On the dividend side, the company has a history of paying cash dividends, though the profitability decline could keep market attention on dividend sustainability.
Ultimately, valuation appears to sit in a range where the pace of profit recovery in the aesthetic product segment and progress in the overseas cosmetics and biopharma pipeline could determine how the market re-rates the stock.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
2025 revenue from the aesthetic product segment rose 14% year-on-year to KRW 59.1 billion, driving overall revenue growth. Growth in the facial aesthetic market and expanding non-surgical treatment options have contributed to demand expansion in this segment. If this trend continues, it could offset margin dilution from the growing distribution business.
Premium brand I.ST has completed entry into Amazon US following participation in European and Middle Eastern beauty trade shows, and is preparing a New York pop-up store for the second half of 2026. Interest from overseas buyers in its pharmacy-based skincare line is also a positive factor for channel expansion.
However, as this is an early stage of new market entry, the scale of revenue contribution still needs to be validated.
GLP-1-class biosimilar and biobetter development for diabetes and obesity treatments has been pursued based on the Sejong pharmaceutical GMP facility. This is viewed as a long-term optionality that could add a new growth axis to the aesthetics-centered business structure.
However, as an early-stage research program, numerous clinical and regulatory steps remain before commercialization.
In 2025, gross margin fell from 46.8% to 41.1% and operating margin dropped sharply from 12.0% to 1.7%. A 89.8% year-on-year surge in R&D spending also weighed on near-term profit. Uncertainty over the pace of profitability recovery remains until improvements in the cost and expense structure are confirmed.
The company posted operating losses in three of the four quarters from Q3 2025 through Q2 2026, and net income attributable to owners was negative for four consecutive quarters.
The possibility that the Q2 2025 profit rebound was a one-off factor cannot be ruled out, meaning stable earnings power has not yet been confirmed.
2025 revenue from the surgical/procedural product segment fell 19% year-on-year to KRW 9.1 billion. Meanwhile, the relatively lower-margin distribution of third-party products expanded to 25.7% of total revenue, which could weigh on the overall profit structure from a product-mix perspective. Continued uneven growth across product lines could slow the recovery of company-wide profitability.
R&D expenses surged 89.8% year-on-year, pressuring near-term profit. As the biopharma pipeline remains at an early stage, development spending may continue, and the timing of any conversion into revenue contribution remains uncertain. If margin recovery falls short of expectations, it could lead to further profitability deterioration.
The filler and botulinum toxin market has seen intensifying competition as numerous players including Hugel, Medytox, and Daewoong Pharmaceutical secure state shipment approvals.
Successive market entries by later entrants could intensify price and share competition, and changes in certification and approval procedures remain a variable that could affect the business.
2025 overseas revenue reached KRW 59.3 billion, a substantial portion of total revenue, exposing the company to currency fluctuations and changes in overseas regulations.
At the same time, the growing weight of the relatively lower-margin distribution business means revenue growth may not directly translate into profit growth.
The Q3 2026 quarterly report is due to be filed, offering a check on whether the operating loss has narrowed further and whether aesthetic product segment revenue recovery continues.
Watch for the opening of the I.ST New York Manhattan pop-up store, its initial reception, and the scale of any North American revenue contribution.
Track the trend in gross margin and R&D expense ratio at upcoming quarterly disclosures to gauge whether the margin decline seen in 2025 has entered a recovery phase.
Monitor for any disclosures regarding preclinical or clinical entry of the GLP-1-class diabetes/obesity pipeline, or discussions of technology licensing.
BNC Korea continued top-line growth in 2025 with revenue of KRW 95.9 billion, but experienced a clear profit-side slowdown as operating margin fell sharply from 12.0% to 1.7%. Operating losses were recorded in three of the last four quarters, meaning earnings stability has yet to be established.
On the other hand, the core aesthetic product segment continues double-digit growth, and the company holds long-term optionality through overseas distribution expansion via its premium cosmetics brand I.ST and its GLP-1 biopharma pipeline based on the Sejong GMP facility.
Balance sheet stability itself appears to remain intact, with a debt ratio of 16.1% and a net operating cash inflow of KRW 7.16 billion. Ultimately, how this stock is assessed may hinge on the pace of near-term margin recovery and whether the overseas cosmetics and biopharma businesses can be monetized.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.